What is Tirzepatide?
Tirzepatide is a peptide designed for weight management that works across two hormone pathways involved in appetite and how the body handles food after eating. This dual action helps reduce hunger, increase fullness and improve metabolic control, giving Tirzepatide an additional pathway compared with GLP-1-only options such as Semaglutide.
Why Tirzepatide?
Powerful Weight Loss
Large human trials have produced substantial results, with higher-dose groups in the landmark SURMOUNT-1 trial averaging around 20% weight loss over 72 weeks.
Appetite Control
Tirzepatide helps reduce hunger and increase fullness, making it easier to eat less and maintain the calorie deficit required for weight loss.
Dual-Action Approach
Unlike GLP-1-only peptides, Tirzepatide also targets GIP, adding a second pathway involved in appetite, nutrient handling and metabolic regulation.
Who is Tirzepatide Popular With?
Tirzepatide is primarily popular with people focused on significant weight loss, particularly those comparing newer weight-management peptides. Its combination of strong appetite control, two complementary hormone pathways and impressive results in large human trials makes it particularly relevant to people comparing it with Semaglutide and other GLP-1-based options.
Research & Evidence
Tirzepatide has extensive human clinical evidence for weight management. Large Phase 3 trials have demonstrated substantial reductions in body weight and waist circumference, while newer head-to-head research has directly compared Tirzepatide with Semaglutide.
SURMOUNT-1 — Up to 20.9% Average Weight Loss
The landmark SURMOUNT-1 trial included 2,539 adults with overweight or obesity without diabetes. After 72 weeks, average weight loss was 15.0% with 5mg, 19.5% with 10mg and 20.9% with 15mg, compared with 3.1% for placebo. In the higher-dose groups, 89–91% of participants lost at least 5% of their starting weight.
SURMOUNT-5 — Greater Weight Loss Than Semaglutide
A 2025 head-to-head trial directly compared Tirzepatide with Semaglutide in 751 adults with obesity without diabetes. After 72 weeks, Tirzepatide produced an average 20.2% reduction in body weight compared with 13.7% for Semaglutide. Average waist circumference fell by 18.4cm with Tirzepatide versus 13.0cm with Semaglutide.
Ready to Get Started?
Use the Add to Cart button below to order Tirzepatide, or get in touch if you have a question first.


Jackson Hendo –
I started out 81kgs. I’m on week 8 I’ve been losing 1kg per week. I have also lost inches around my body. My clothes fit better no inflammation. I started at 2 mg first for 4 weeks then I went up 3mg.
sarah groverly –
Well, 18 years, 3 months, 3 days later… Thanks to Tirzepatide and a couple 🩶 other things, I finally truly meet the military weight standards. At 43 years old, I need to be 80kg or less to avoid being taped for BMI. It has never happened so I consider this a HUGE win!